loading
Avalo Therapeutics Inc stock is traded at $10.40, with a volume of 10,595. It is down -2.89% in the last 24 hours and down -7.88% over the past month. Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
See More
Previous Close:
$10.90
Open:
$10.69
24h Volume:
10,595
Relative Volume:
0.29
Market Cap:
$110.59M
Revenue:
$1.93M
Net Income/Loss:
$-7.96M
P/E Ratio:
-4.8598
EPS:
-2.14
Net Cash Flow:
$-36.78M
1W Performance:
-21.48%
1M Performance:
-7.88%
6M Performance:
-3.07%
1Y Performance:
+11,661%
1-Day Range:
Value
$10.31
$10.69
1-Week Range:
Value
$10.33
$13.50
52-Week Range:
Value
$0.0333
$34.46

Avalo Therapeutics Inc Stock (AVTX) Company Profile

Name
Name
Avalo Therapeutics Inc
Name
Phone
410-522-8707
Name
Address
540 GAITHER ROAD, ROCKVILLE
Name
Employee
19
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
AVTX's Discussions on Twitter

Compare AVTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
AVTX 10.38 110.59M 1.93M -7.96M -36.78M -2.14
VRTX 446.37 115.74B 10.63B -479.80M -1.35B 13.33
REGN 740.39 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 592.20 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.97 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.80 24.49B 3.30B -501.07M 1.03B 11.54

Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-24-21 Initiated RBC Capital Mkts Outperform

Avalo Therapeutics Inc Stock (AVTX) Latest News

pulisher
01:04 AM

Avalo Therapeutics (FRA:C6K0) Cyclically Adjusted PS Ratio : 0.02 (As of Nov. 21, 2024) - GuruFocus.com

01:04 AM
pulisher
Nov 17, 2024

(AVTX) Investment Analysis and Advice - Stock Traders Daily

Nov 17, 2024
pulisher
Nov 15, 2024

Orbimed Advisors LLC Acquires New Stake in Avalo Therapeutics Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Avalo Therapeutics director June Almenoff acquires $12,749 in stock - Investing.com

Nov 14, 2024
pulisher
Nov 14, 2024

Avalo Therapeutics receives $69.4M in proceeds from full exercise of private placement warrants - MSN

Nov 14, 2024
pulisher
Nov 13, 2024

Avalo Therapeutics secures $69.4 million from warrant exercise By Investing.com - Investing.com Australia

Nov 13, 2024
pulisher
Nov 12, 2024

Avalo Therapeutics Closes $69.4 Million Financing - citybiz

Nov 12, 2024
pulisher
Nov 12, 2024

Avalo Therapeutics receives $69.4M in proceeds from exercise of warrants - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

Avalo Therapeutics secures $69.4 million from warrant exercise - Investing.com India

Nov 12, 2024
pulisher
Nov 12, 2024

Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants - GlobeNewswire

Nov 12, 2024
pulisher
Nov 12, 2024

Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants - GlobeNewswire Inc.

Nov 12, 2024
pulisher
Nov 11, 2024

Avalo Therapeutics to Present at Upcoming Investor Conferences - The Manila Times

Nov 11, 2024
pulisher
Nov 07, 2024

Avalo Therapeutics reports Q3 EPS ($2.83) vs ($22.83) last year - TipRanks

Nov 07, 2024
pulisher
Nov 07, 2024

Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates - GlobeNewswire

Nov 07, 2024
pulisher
Nov 07, 2024

Avalo Therapeutics Inc (AVTX) Quarterly 10-Q Report - Quartzy

Nov 07, 2024
pulisher
Nov 06, 2024

Where are the Opportunities in (AVTX) - Stock Traders Daily

Nov 06, 2024
pulisher
Oct 28, 2024

Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews

Oct 28, 2024
pulisher
Oct 26, 2024

Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated at HC Wainwright - Defense World

Oct 26, 2024
pulisher
Oct 15, 2024

When (AVTX) Moves Investors should Listen - Stock Traders Daily

Oct 15, 2024
pulisher
Oct 08, 2024

Avalo Therapeutics begins Phase 2 trial for hidradenitis suppurativa - Investing.com

Oct 08, 2024
pulisher
Oct 08, 2024

Avalo Therapeutics maintains Outperform rating from Oppenheimer - Investing.com

Oct 08, 2024
pulisher
Oct 08, 2024

Avalo Therapeutics begins Phase 2 trial for hidradenitis suppurativa By Investing.com - Investing.com UK

Oct 08, 2024
pulisher
Oct 08, 2024

Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial - GlobeNewswire

Oct 08, 2024
pulisher
Oct 08, 2024

Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa - Yahoo Finance

Oct 08, 2024
pulisher
Oct 08, 2024

Ikarian Capital, LLC Adjusts Stake in Avalo Therapeutics Inc - GuruFocus.com

Oct 08, 2024
pulisher
Oct 05, 2024

(AVTX) Technical Pivots with Risk Controls - Stock Traders Daily

Oct 05, 2024
pulisher
Sep 27, 2024

Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Expands By 38.1% - Defense World

Sep 27, 2024
pulisher
Sep 25, 2024

Avalo Therapeutics: Pioneering Biotech Solutions for Immune Disorders - The China Perspective

Sep 25, 2024
pulisher
Sep 25, 2024

Affinity Asset Advisors LLC Acquires 35,000 Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Defense World

Sep 25, 2024
pulisher
Sep 24, 2024

Logos Global Management LP Purchases New Position in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Defense World

Sep 24, 2024
pulisher
Sep 13, 2024

How To Trade (AVTX) - Stock Traders Daily

Sep 13, 2024
pulisher
Sep 10, 2024

Avalo Therapeutics (NASDAQ:AVTX) Stock Price Up 7.8% - Defense World

Sep 10, 2024
pulisher
Sep 04, 2024

Avalo Therapeutics regains Nasdaq compliance - Investing.com

Sep 04, 2024
pulisher
Sep 04, 2024

Avalo Announces Participation in September Investor Conferences - GlobeNewswire

Sep 04, 2024
pulisher
Sep 02, 2024

Financial Health Report: Avalo Therapeutics Inc (AVTX)’s Ratios Tell a Tale - The Dwinnex

Sep 02, 2024
pulisher
Aug 29, 2024

Trading (AVTX) With Integrated Risk Controls - Stock Traders Daily

Aug 29, 2024
pulisher
Aug 19, 2024

Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Down 9.6% in July - Defense World

Aug 19, 2024
pulisher
Aug 18, 2024

Avalo Therapeutics (FRA:C6K0) Cash From Discontinued Investing Activities : €0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com

Aug 18, 2024
pulisher
Aug 15, 2024

Oppenheimer sees upside in Avalo Therapeutics stock as phase 2 trial nears - Investing.com

Aug 15, 2024
pulisher
Aug 14, 2024

Avalo Therapeutics (NASDAQ:AVTX) Releases Earnings Results - Defense World

Aug 14, 2024
pulisher
Aug 14, 2024

Avalo Therapeutics Shareholders Back Board and Strategies - TipRanks

Aug 14, 2024
pulisher
Aug 13, 2024

Avalo Therapeutics sees cash runway into 2027 - TipRanks

Aug 13, 2024
pulisher
Aug 12, 2024

AVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q2 2024 - InvestorPlace

Aug 12, 2024
pulisher
Aug 12, 2024

Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates - citybiz

Aug 12, 2024
pulisher
Aug 09, 2024

Avalo Therapeutics Inc expected to post a loss of $6.70 a shareEarnings Preview - XM

Aug 09, 2024
pulisher
Jul 28, 2024

Natixis Lowers Stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Defense World

Jul 28, 2024
pulisher
Jul 26, 2024

(AVTX) Long Term Investment Analysis - Stock Traders Daily

Jul 26, 2024
pulisher
Jul 24, 2024

The 3 Best Personalized Nutrition Stocks to Buy Now - InvestorPlace

Jul 24, 2024
pulisher
Jul 24, 2024

Avalo Therapeutics (NASDAQ:AVTX) Shares Down 2.1% - Defense World

Jul 24, 2024
pulisher
Jul 16, 2024

Avalo Therapeutics welcomes new Chief Medical Officer - Investing.com

Jul 16, 2024
pulisher
Jul 16, 2024

Avalo Therapeutics Welcomes Chief Medical Officer - Contract Pharma

Jul 16, 2024

Avalo Therapeutics Inc Stock (AVTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):